Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes

Hung Yuan Li, Yi Der Jiang, Tien Jyun Chang, Jung Nan Wei, Mao Shin Lin, Cheng Hsin Lin, Fu Tien Chiang, Shyang Rong Shih, Chi Sheng Hung, Cyue Huei Hua, David J. Smith, Jani Vanio, Lee Ming Chuang

研究成果: 雜誌貢獻文章

42 引文 (Scopus)

摘要

OBJECTIVE - Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS - The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17-4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17-28.97) for cardiovascular mortality, 6.32 (95% CI 1.25-32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57-65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS - Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors.

原文英語
頁(從 - 到)993-999
頁數7
期刊Diabetes
60
發行號3
DOIs
出版狀態已發佈 - 三月 2011

指紋

Type 2 Diabetes Mellitus
Blood Vessels
Mortality
Serum
Neoplasms
Proteins
Glomerular Filtration Rate
Taiwan
Proteinuria
Fluoroimmunoassay
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ankle Brachial Index
Death Certificates
Ammonia
Aldehydes
Hyperglycemia
Hydrogen Peroxide
Amines
Hemoglobins
Cohort Studies

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

引用此文

Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. / Li, Hung Yuan; Jiang, Yi Der; Chang, Tien Jyun; Wei, Jung Nan; Lin, Mao Shin; Lin, Cheng Hsin; Chiang, Fu Tien; Shih, Shyang Rong; Hung, Chi Sheng; Hua, Cyue Huei; Smith, David J.; Vanio, Jani; Chuang, Lee Ming.

於: Diabetes, 卷 60, 編號 3, 03.2011, p. 993-999.

研究成果: 雜誌貢獻文章

Li, HY, Jiang, YD, Chang, TJ, Wei, JN, Lin, MS, Lin, CH, Chiang, FT, Shih, SR, Hung, CS, Hua, CH, Smith, DJ, Vanio, J & Chuang, LM 2011, 'Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes', Diabetes, 卷 60, 編號 3, 頁 993-999. https://doi.org/10.2337/db10-0607
Li, Hung Yuan ; Jiang, Yi Der ; Chang, Tien Jyun ; Wei, Jung Nan ; Lin, Mao Shin ; Lin, Cheng Hsin ; Chiang, Fu Tien ; Shih, Shyang Rong ; Hung, Chi Sheng ; Hua, Cyue Huei ; Smith, David J. ; Vanio, Jani ; Chuang, Lee Ming. / Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. 於: Diabetes. 2011 ; 卷 60, 編號 3. 頁 993-999.
@article{eab25c8466c948798c6cfc83dacd5472,
title = "Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes",
abstract = "OBJECTIVE - Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS - The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95{\%} CI 1.17-4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95{\%} CI 1.17-28.97) for cardiovascular mortality, 6.32 (95{\%} CI 1.25-32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95{\%} CI 4.57-65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS - Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors.",
author = "Li, {Hung Yuan} and Jiang, {Yi Der} and Chang, {Tien Jyun} and Wei, {Jung Nan} and Lin, {Mao Shin} and Lin, {Cheng Hsin} and Chiang, {Fu Tien} and Shih, {Shyang Rong} and Hung, {Chi Sheng} and Hua, {Cyue Huei} and Smith, {David J.} and Jani Vanio and Chuang, {Lee Ming}",
year = "2011",
month = "3",
doi = "10.2337/db10-0607",
language = "English",
volume = "60",
pages = "993--999",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes

AU - Li, Hung Yuan

AU - Jiang, Yi Der

AU - Chang, Tien Jyun

AU - Wei, Jung Nan

AU - Lin, Mao Shin

AU - Lin, Cheng Hsin

AU - Chiang, Fu Tien

AU - Shih, Shyang Rong

AU - Hung, Chi Sheng

AU - Hua, Cyue Huei

AU - Smith, David J.

AU - Vanio, Jani

AU - Chuang, Lee Ming

PY - 2011/3

Y1 - 2011/3

N2 - OBJECTIVE - Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS - The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17-4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17-28.97) for cardiovascular mortality, 6.32 (95% CI 1.25-32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57-65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS - Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors.

AB - OBJECTIVE - Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 correlates positively with both acute hyperglycemia and diabetes. We conducted a cohort study to evaluate whether serum VAP-1 predicts 10-year survival in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Between July 1996 and June 2003, we enrolled 661 type 2 diabetic subjects at National Taiwan University Hospital. Serum VAP-1 in the samples obtained at enrollment was measured by time-resolved immunofluorometric assay. The vital status of all subjects was ascertained by linking their data with computerized death certificates in Taiwan. RESULTS - The medium follow-up period was 10.4 years. Subjects with serum VAP-1 in the highest tertile had a hazard ratio (HR) of 2.19 (95% CI 1.17-4.11) for all-cause mortality adjusted for age, sex, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1c, diabetes duration, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. The adjusted HRs for logarithmically transformed serum VAP-1 were 5.83 (95% CI 1.17-28.97) for cardiovascular mortality, 6.32 (95% CI 1.25-32.00) for mortality from cardiovascular and diabetic causes, and 17.24 (95% CI 4.57-65.07) for cancer mortality. There were four variables, including age, serum VAP-1, proteinuria, and eGFR, which could enhance mortality prediction significantly. CONCLUSIONS - Serum VAP-1 can predict 10-year all-cause mortality, cardiovascular mortality, and cancer mortality independently in type 2 diabetic subjects. Serum VAP-1 is a novel biomarker that improves risk prediction over and above established risk factors.

UR - http://www.scopus.com/inward/record.url?scp=79952367891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952367891&partnerID=8YFLogxK

U2 - 10.2337/db10-0607

DO - 10.2337/db10-0607

M3 - Article

C2 - 21282368

AN - SCOPUS:79952367891

VL - 60

SP - 993

EP - 999

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -